CASP8 and bladder transitional cell carcinoma: Furthermore, we also assessed the impact of the CASP8 expression on the drug sensitivity of various targeted therapies for BLCA based on the data from the GDSC database using the R package “pRRophetic.” Our results suggested that the expression level of CASP8 in BLCA could affect the drug sensitivities (IC50) of FR-180204 (an ERK inhibitor), LY317615 (a PKCβ inhibitor), JNK VIII inhibitor, gefitinib (EGFR inhibitor), SNX-2112 (HSP inhibitor), and lapatinib (an EGFR/HER2 tyrosine kinase inhibitor) (p < 0.001, for all) (Supplementary Figure S1).